{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:51:04Z","timestamp":1792511464558,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s40262-024-01428-6","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T06:58:54Z","timestamp":1730185134000},"page":"1513-1528","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Clinical Pharmacology of Asciminib: A Review"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1033-2716","authenticated-orcid":false,"given":"Matthias","family":"Hoch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7121-4394","authenticated-orcid":false,"given":"Felix","family":"Huth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul William","family":"Manley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2586-3577","authenticated-orcid":false,"given":"Ioannis","family":"Loisios-Konstantinidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8637-7372","authenticated-orcid":false,"given":"Francois Pierre","family":"Combes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1406-8538","authenticated-orcid":false,"given":"Ying Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2988-4447","authenticated-orcid":false,"given":"Yunlin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6405-9130","authenticated-orcid":false,"given":"Sherwin K. B.","family":"Sy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Obourn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3076-6587","authenticated-orcid":false,"given":"Abhijit","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Hourcade-Potelleret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"issue":"13","key":"1428_CR1","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.3390\/cells12131703","volume":"12","author":"M Iezza","year":"2023","unstructured":"Iezza M, Cortesi S, Ottaviani E, Mancini M, Venturi C, Monaldi C, et al. Prognosis in chronic myeloid leukemia: baseline factors, dynamic risk assessment and novel insights. Cells. 2023;12(13):1703.","journal-title":"Cells"},{"key":"1428_CR2","volume-title":"Cancer II topics in medicinal chemistry","author":"PW Manley","year":"2017","unstructured":"Manley PW, Stiefl NJ. Progress in the discovery of BCR-ABL kinase inhibitors for the treatment of leukemia. In: Waring MJ, editor. Cancer II topics in medicinal chemistry. Cham: Springer; 2017."},{"issue":"11","key":"1428_CR3","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","volume":"20","author":"MM Attwood","year":"2021","unstructured":"Attwood MM, Fabbro D, Sokolov AV, Knapp S, Schi\u00f6th HB. Trends in kinase drug discovery: targets, indications and inhibitor design. Nat Rev Drug Discov. 2021;20(11):839\u201361.","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"1428_CR4","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","volume":"30","author":"JL Steegmann","year":"2016","unstructured":"Steegmann JL, Baccarani M, Breccia M, Casado LF, Garc\u00eda-Guti\u00e9rrez V, Hochhaus A, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30(8):1648\u201371.","journal-title":"Leukemia"},{"issue":"21","key":"1428_CR5","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.2020009984","volume":"138","author":"D R\u00e9a","year":"2021","unstructured":"R\u00e9a D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138(21):2031\u201341.","journal-title":"Blood"},{"issue":"3","key":"1428_CR6","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41375-023-01829-9","volume":"37","author":"A Hochhaus","year":"2023","unstructured":"Hochhaus A, R\u00e9a D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, et al. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia. 2023;37(3):617\u201326.","journal-title":"Leukemia"},{"key":"1428_CR7","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106458","volume":"98","author":"PW Manley","year":"2020","unstructured":"Manley PW, Barys L, Cowan-Jacob SW. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. Leuk Res. 2020;98: 106458.","journal-title":"Leuk Res"},{"key":"1428_CR8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2020-139677","volume":"136","author":"JE Cortes","year":"2020","unstructured":"Cortes JE, Hughes TP, Mauro MJ, Hochhaus A, Rea D, Goh YT, et al. Asciminib, a first-in-class STAMP inhibitor, provides durable molecular response in patients (pts) with chronic myeloid leukemia (CML) harboring the T315I mutation: primary efficacy and safety results from a phase 1 trial. Blood. 2020;136:47\u201350.","journal-title":"Blood"},{"issue":"6","key":"1428_CR9","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/cncr.25527","volume":"117","author":"J Cortes","year":"2011","unstructured":"Cortes J, Quint\u00e1s-Cardama A, Kantarjian HM. Monitoring molecular response in chronic myeloid leukemia. Cancer. 2011;117(6):1113\u201322.","journal-title":"Cancer"},{"issue":"4","key":"1428_CR10","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966\u201384.","journal-title":"Leukemia"},{"issue":"24","key":"1428_CR11","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","volume":"381","author":"TP Hughes","year":"2019","unstructured":"Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019;381(24):2315\u201326.","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"1428_CR12","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.1182\/blood-2022-163078","volume":"140","author":"FP Combes","year":"2022","unstructured":"Combes FP, Li YF, Sy SKB, Lorenzo S, Dasgupta K, Kapoor S, et al. Justification for asciminib dosing in patients with philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML-CP) with and without the T315I mutation. Blood. 2022;140(Supplement 1):6791\u20132.","journal-title":"Blood"},{"issue":"5","key":"1428_CR13","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1002\/cpt.2699","volume":"112","author":"FP Combes","year":"2022","unstructured":"Combes FP, Li YF, Hoch M, Lorenzo S, Ho YY, Sy SKB. Exposure-efficacy analysis of asciminib in philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Clin Pharmacol Ther. 2022;112(5):1040\u201350.","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"1428_CR14","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s40262-022-01148-9","volume":"61","author":"YF Li","year":"2022","unstructured":"Li YF, Combes FP, Hoch M, Lorenzo S, Sy SKB, Ho YY. Population pharmacokinetics of asciminib in tyrosine kinase inhibitor-treated patients with philadelphia chromosome-positive chronic myeloid leukemia in chronic and acute phases. Clin Pharmacokinet. 2022;61(10):1393\u2013403.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"1428_CR15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nchembio760","volume":"2","author":"FJ Adri\u00e1n","year":"2006","unstructured":"Adri\u00e1n FJ, Ding Q, Sim T, Velentza A, Sloan C, Liu Y, et al. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol. 2006;2(2):95\u2013102.","journal-title":"Nat Chem Biol"},{"issue":"6","key":"1428_CR16","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0092-8674(03)00194-6","volume":"112","author":"B Nagar","year":"2003","unstructured":"Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, Bornmann W, et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell. 2003;112(6):859\u201371.","journal-title":"Cell"},{"issue":"6","key":"1428_CR17","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0092-8674(03)00191-0","volume":"112","author":"O Hantschel","year":"2003","unstructured":"Hantschel O, Nagar B, Guettler S, Kretzschmar J, Dorey K, Kuriyan J, et al. A myristoyl\/phosphotyrosine switch regulates c-Abl. Cell. 2003;112(6):845\u201357.","journal-title":"Cell"},{"issue":"6","key":"1428_CR18","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.chembiol.2013.06.001","volume":"20","author":"DK Treiber","year":"2013","unstructured":"Treiber DK, Shah NP. Ins and outs of kinase DFG motifs. Chem Biol. 2013;20(6):745\u20136.","journal-title":"Chem Biol"},{"issue":"18","key":"1428_CR19","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","volume":"61","author":"J Schoepfer","year":"2018","unstructured":"Schoepfer J, Jahnke W, Berellini G, Buonamici S, Cotesta S, Cowan-Jacob SW, et al. Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1. J Med Chem. 2018;61(18):8120\u201335.","journal-title":"J Med Chem"},{"issue":"7280","key":"1428_CR20","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nature08675","volume":"463","author":"J Zhang","year":"2010","unstructured":"Zhang J, Adri\u00e1n FJ, Jahnke W, Cowan-Jacob SW, Li AG, Iacob RE, et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature. 2010;463(7280):501\u20136.","journal-title":"Nature"},{"issue":"7647","key":"1428_CR21","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","volume":"543","author":"AA Wylie","year":"2017","unstructured":"Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature. 2017;543(7647):733\u20137.","journal-title":"Nature"},{"key":"1428_CR22","unstructured":"FDA. Scemblix. Multidisciplinary review and evaluation; 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/207997Orig1Orig2s000ClinPharmR.pdf. Accessed 17 Oct 2024."},{"issue":"7","key":"1428_CR23","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41589-018-0077-5","volume":"14","author":"B Castrec","year":"2018","unstructured":"Castrec B, Dian C, Ciccone S, Ebert CL, Bienvenut WV, Le Caer JP, et al. Structural and genomic decoding of human and plant myristoylomes reveals a definitive recognition pattern. Nat Chem Biol. 2018;14(7):671\u20139.","journal-title":"Nat Chem Biol"},{"issue":"4","key":"1428_CR24","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/s41423-021-00663-2","volume":"18","author":"B Wang","year":"2021","unstructured":"Wang B, Dai T, Sun W, Wei Y, Ren J, Zhang L, et al. Protein N-myristoylation: functions and mechanisms in control of innate immunity. Cell Mol Immunol. 2021;18(4):878\u201388.","journal-title":"Cell Mol Immunol"},{"key":"1428_CR25","volume":"13","author":"H Zhang","year":"2022","unstructured":"Zhang H, Zhu M, Li M, Ni D, Wang Y, Deng L, et al. Mechanistic insights into co-administration of allosteric and orthosteric drugs to overcome drug-resistance in T315I BCR-ABL1. Front Pharmacol. 2022;13: 862504.","journal-title":"Front Pharmacol"},{"key":"1428_CR26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102837","volume":"57","author":"R Ietswaart","year":"2020","unstructured":"Ietswaart R, Arat S, Chen AX, Farahmand S, Kim B, DuMouchel W, et al. Machine learning guided association of adverse drug reactions with in vitro target-based pharmacology. EBioMedicine. 2020;57: 102837.","journal-title":"EBioMedicine"},{"key":"1428_CR27","unstructured":"Novartis. Data on file."},{"issue":"14","key":"1428_CR28","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.3390\/cancers14143300","volume":"14","author":"G Poudel","year":"2022","unstructured":"Poudel G, Tolland MG, Hughes TP, Pagani IS. Mechanisms of resistance and implications for treatment strategies in chronic myeloid leukaemia. Cancers (Basel). 2022;14(14):3300.","journal-title":"Cancers (Basel)."},{"issue":"2","key":"1428_CR29","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1080\/00498254.2019.1594449","volume":"50","author":"P Tran","year":"2020","unstructured":"Tran P, Hanna I, Eggimann FK, Schoepfer J, Ray T, Zhu B, et al. Disposition of asciminib, a potent BCR-ABL1 tyrosine kinase inhibitor, in healthy male subjects. Xenobiotica. 2020;50(2):150\u201369.","journal-title":"Xenobiotica"},{"issue":"59","key":"1428_CR30","volume":"1","author":"PW Manley","year":"2022","unstructured":"Manley PW, Huth F, Moussaoui S, Schoepfer J. A kinase inhibitor which specifically targets the ABL myristate pocket (STAMP), but unlike asciminib crosses the blood-brain barrier. Bioorg Med Chem Lett. 2022;1(59): 128577.","journal-title":"Bioorg Med Chem Lett"},{"issue":"19","key":"1428_CR31","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.3390\/cancers13194820","volume":"13","author":"R Alves","year":"2021","unstructured":"Alves R, Gon\u00e7alves AC, Rutella S, Almeida AM, De Las Rivas J, Trougakos IP, et al. Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia-from molecular mechanisms to clinical relevance. Cancers (Basel). 2021;13(19):4820.","journal-title":"Cancers (Basel)."},{"issue":"17","key":"1428_CR32","doi-asserted-by":"crossref","first-page":"13423","DOI":"10.18632\/oncotarget.24393","volume":"9","author":"LN Eadie","year":"2018","unstructured":"Eadie LN, Saunders VA, Branford S, White DL, Hughes TP. The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro. Oncotarget. 2018;9(17):13423\u201337.","journal-title":"Oncotarget"},{"issue":"12","key":"1428_CR33","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1038\/leu.2017.264","volume":"31","author":"W Qiang","year":"2017","unstructured":"Qiang W, Antelope O, Zabriskie MS, Pomicter AD, Vellore NA, Szankasi P, et al. Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib. Leukemia. 2017;31(12):2844\u20137.","journal-title":"Leukemia"},{"issue":"46","key":"1428_CR34","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202117276","volume":"61","author":"W Jahnke","year":"2022","unstructured":"Jahnke W, Paladini J, Habazettl JM, Wiget A, Loo A, Cowan Jacob SW, et al. Correspondence on \u201cSynergy and antagonism between allosteric and active-site inhibitors of Abl tyrosine kinase.\u201d Angew Chem Int Ed Engl. 2022;61(46): e202117276.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"37","key":"1428_CR35","doi-asserted-by":"crossref","first-page":"20196","DOI":"10.1002\/anie.202105351","volume":"60","author":"TK Johnson","year":"2021","unstructured":"Johnson TK, Bochar DA, Vandecan NM, Furtado J, Agius MP, Phadke S, et al. Synergy and antagonism between allosteric and active-site inhibitors of Abl tyrosine kinase. Angew Chem Int Ed Engl. 2021;60(37):20196\u20139.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"46","key":"1428_CR36","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202209518","volume":"61","author":"TK Johnson","year":"2022","unstructured":"Johnson TK, Bochar DA, Vandecan NM, Furtado J, Agius MP, Phadke S, et al. Reply to correspondence on \u201cSynergy and antagonism between allosteric and active-site inhibitors of Abl tyrosine kinase.\u201d Angew Chem Int Ed Engl. 2022;61(46): e202209518.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"8","key":"1428_CR37","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102238","volume":"298","author":"B Oruganti","year":"2022","unstructured":"Oruganti B, Lindahl E, Yang J, Amiri W, Rahimullah R, Friedman R. Allosteric enhancement of the BCR-Abl1 kinase inhibition activity of nilotinib by cobinding of asciminib. J Biol Chem. 2022;298(8): 102238.","journal-title":"J Biol Chem"},{"issue":"2","key":"1428_CR38","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/cpdd.1019","volume":"11","author":"M Hoch","year":"2022","unstructured":"Hoch M, Zack J, Quinlan M, Huth F, Forte S, Dodd S, et al. Pharmacokinetics of asciminib when taken with imatinib or with food. Clin Pharmacol Drug Dev. 2022;11(2):207\u201319.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"11","key":"1428_CR39","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/jcph.1926","volume":"61","author":"M Hoch","year":"2021","unstructured":"Hoch M, Sato M, Zack J, Quinlan M, Sengupta T, Allepuz A, et al. Pharmacokinetics of asciminib in individuals with hepatic or renal impairment. J Clin Pharmacol. 2021;61(11):1454\u201365.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"1428_CR40","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0950-3536(97)80003-0","volume":"10","author":"JV Melo","year":"1997","unstructured":"Melo JV. BCR-ABL gene variants. Baillieres Clin Haematol. 1997;10(2):203\u201322.","journal-title":"Baillieres Clin Haematol"},{"key":"1428_CR41","unstructured":"Novartis. Scemblix summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/scemblix-epar-product-information_en.pdf. Accessed 5 Apr 2024."},{"issue":"7","key":"1428_CR42","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1111\/cts.13285","volume":"15","author":"M Hoch","year":"2022","unstructured":"Hoch M, Huth F, Sato M, Sengupta T, Quinlan M, Dodd S, et al. Pharmacokinetics of asciminib in the presence of CYP3A or P-gp inhibitors, CYP3A inducers, and acid-reducing agents. Clin Transl Sci. 2022;15(7):1698\u2013712.","journal-title":"Clin Transl Sci"},{"issue":"3","key":"1428_CR43","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/cpdd.602","volume":"8","author":"HD Menssen","year":"2019","unstructured":"Menssen HD, Quinlan M, Kemp C, Tian X. Relative bioavailability and food effect evaluation for 2 tablet formulations of asciminib in a 2-arm, crossover, randomized, open-label study in healthy volunteers. Clin Pharmacol Drug Dev. 2019;8(3):385\u201394.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"5","key":"1428_CR44","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/cpdd.1213","volume":"12","author":"M Hoch","year":"2023","unstructured":"Hoch M, Bebrevska L, Singh N, Hourcade-Potelleret F. Relative bioavailability and food effect of asciminib pediatric mini-tablet formulation compared to the reference tablet formulation in healthy adult participants. Clin Pharmacol Drug Dev. 2023;12(5):484\u201392.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"5","key":"1428_CR45","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/s41375-023-01860-w","volume":"37","author":"MJ Mauro","year":"2023","unstructured":"Mauro MJ, Hughes TP, Kim DW, Rea D, Cortes JE, Hochhaus A, et al. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results. Leukemia. 2023;37(5):1048\u201359.","journal-title":"Leukemia"},{"issue":"6","key":"1428_CR46","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/clpt.2008.59","volume":"83","author":"TD Nolin","year":"2008","unstructured":"Nolin TD, Naud J, Leblond FA, Pichette V. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther. 2008;83(6):898\u2013903.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"1428_CR47","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/cts.13252","volume":"15","author":"M Hoch","year":"2022","unstructured":"Hoch M, Sengupta T, Hourcade-Potelleret F. Pharmacokinetic drug interactions of asciminib with the sensitive cytochrome P450 probe substrates midazolam, warfarin, and repaglinide in healthy participants. Clin Transl Sci. 2022;15(6):1406\u201316.","journal-title":"Clin Transl Sci"},{"key":"1428_CR48","unstructured":"Asciminib SmPC. 2022."},{"key":"1428_CR49","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/blood-2021-152561","volume":"138 (Suppl 1)","author":"MJ Mauro","year":"2021","unstructured":"Mauro MJ, Minami Y, Rea D, Hochhaus A, Lomaia E, Voloshin S, et al. Efficacy and safety results from ascembl, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib in patients with chronic myeloid leukemia in chronic phase after \u22652 prior tyrosine kinase inhibitors: update after 48 weeks. Blood. 2021;138(Suppl 1):310.","journal-title":"Blood"},{"issue":"9","key":"1428_CR50","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.1007\/s00432-022-04562-5","volume":"149","author":"E Atallah","year":"2023","unstructured":"Atallah E, Mauro MJ, Hochhaus A, Boquimpani C, Minami Y, Maheshwari VK, et al. Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors. J Cancer Res Clin Oncol. 2023;149(9):6247\u201362.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1428_CR51","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, et al. Asciminib in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2024;391(10):885\u201398.","DOI":"10.1056\/NEJMoa2400858"},{"issue":"S1","key":"1428_CR52","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/01.HS9.0000561812.22500.d8","volume":"3","author":"J Cortes","year":"2019","unstructured":"Cortes J, Lang F, Kim D-W, Rea D, Mauro M, Minami H, et al. Combination therapy using asciminib plus imatinib (IMA) in patients (pts) with chronic myeloid leukemia (CML): results from a phase 1 study. Hemasphere. 2019;3(S1):397.","journal-title":"Hemasphere."},{"key":"1428_CR53","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1182\/blood-2022-167177","volume":"140","author":"JE Cortes","year":"2022","unstructured":"Cortes JE, Hughes T, Geissler J, Kim D-W, Lomaia E, Mayer J, et al. Efficacy and safety results from ASC4MORE, a randomized study of asciminib (ASC) add-on to imatinib (IMA), continued IMA, or switch to nilotinib (NIL) in patients (Pts) with chronic-phase chronic myeloid leukemia (CML-CP) not achieving deep molecular responses (DMRs) with \u22651 year of IMA. Blood. 2022;140:195\u20137.","journal-title":"Blood"},{"key":"1428_CR54","doi-asserted-by":"crossref","unstructured":"Ernst T, Le Coutre P, Crysandt M, Br\u00fcmmendorf TH, Franke GN, Illmer T, et al. S156: frontline asciminib combination in chronic phase chronic myeloid leukemia patients. THE FASCINATION TRIAL. Hemasphere. 2023;7(Suppl):e34543a6.","DOI":"10.1097\/01.HS9.0000967536.34543.a6"},{"issue":"11","key":"1428_CR55","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.3324\/haematol.2018.194522","volume":"103","author":"AC Fassoni","year":"2018","unstructured":"Fassoni AC, Baldow C, Roeder I, Glauche I. Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data. Haematologica. 2018;103(11):1825\u201334.","journal-title":"Haematologica"},{"key":"1428_CR56","doi-asserted-by":"crossref","unstructured":"Combes FP, Li YF, Sy SKB, Lorenzo S, Dasgupta K, Kapoor S, et al. Justification for asciminib dosing in patients with philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML-CP) with and without the T315I mutation. American Society for Hematology; 2022 December 10\u201313; New Orleans; 2022.","DOI":"10.1182\/blood-2022-163078"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01428-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-024-01428-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01428-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T16:06:53Z","timestamp":1731946013000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-024-01428-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":56,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1428"],"URL":"https:\/\/doi.org\/10.1007\/s40262-024-01428-6","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,29]]},"assertion":[{"value":"6 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by Novartis Pharma AG.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors are employees of Novartis. M.H., F.P.C., and A.C. are also Novartis stockholders.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"M.H. conceived the article. All authors performed the literature search, drafted, and\/or critically revised the work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}